Cue Biopharma Files Definitive Proxy Statement
Ticker: CUE · Form: DEF 14A · Filed: Sep 10, 2024 · CIK: 1645460
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
Cue Biopharma dropped its proxy statement, shareholders vote soon.
AI Summary
Cue Biopharma, Inc. filed its definitive proxy statement (DEF 14A) on September 10, 2024, for its annual meeting of stockholders. The filing provides details regarding the company's governance, executive compensation, and proposals to be voted on by shareholders. The company, formerly known as Imagen Biopharma, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This filing is crucial for shareholders as it outlines the company's strategic direction, executive compensation packages, and key decisions that will be put to a vote, impacting the company's future performance and governance.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new material financial information or strategic shifts that would inherently increase risk.
Key Players & Entities
- Cue Biopharma, Inc. (company) — Registrant
- Imagen Biopharma, Inc. (company) — Former company name
- 0000950170-24-105104 (filing_id) — Accession Number
- 20240910 (date) — Filing Date
- 20241008 (date) — Period of Report
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a definitive proxy statement, is filed by a company with the SEC to solicit proxy votes from its shareholders for an upcoming shareholder meeting.
When was Cue Biopharma, Inc.'s definitive proxy statement filed?
Cue Biopharma, Inc.'s definitive proxy statement was filed on September 10, 2024.
What was Cue Biopharma, Inc.'s former company name?
Cue Biopharma, Inc.'s former company name was Imagen Biopharma, Inc., with a date of name change on June 17, 2015.
Where is Cue Biopharma, Inc. incorporated?
Cue Biopharma, Inc. is incorporated in Delaware (DE).
What is the Standard Industrial Classification (SIC) code for Cue Biopharma, Inc.?
The Standard Industrial Classification (SIC) code for Cue Biopharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,854 words · 19 min read · ~16 pages · Grade level 9.8 · Accepted 2024-09-10 16:00:02
Key Financial Figures
- $9,000 — for service fees of up to approximately $9,000. Q. Whom should I contact if I have a
Filing Documents
- def_14a_special_proxy_20.htm (DEF 14A) — 327KB
- img217891312_0.jpg (GRAPHIC) — 31KB
- img217891312_1.jpg (GRAPHIC) — 31KB
- img217891312_2.jpg (GRAPHIC) — 120KB
- img217891312_3.jpg (GRAPHIC) — 58KB
- 0000950170-24-105104.txt ( ) — 658KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 7 PROPOSAL 1: ADOPTION AND APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF OUR CAPITAL STOCK AND COMMON STOCK 9 Purpose 9 Possible Effects of the Amendment 10 Reservation of Right to Abandon the Amendment 10 Recommendation of the Board of Directors 10 PROPOSAL 2: ADJOURNMENT PROPOSAL 12 Recommendation of the Board of Directors 12 OTHER MATTERS 13 Stockholder Proposals for 2025 Annual Meeting 13 Householding of Special Meeting Materials 13 APPENDIX A: CERTIFICATE OF AMENDMENT 15 CUE BIOPHARMA, INC. 40 Guest Street Boston, Massachusetts 02135 PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS To Be Held on Tuesday, October 8, 2024 INFORMATION CONCERNING SOLICITATION AND VOTING This Proxy Statement contains information about our special meeting of stockholders, or the Special Meeting. The meeting will be held on Tuesday, October 8, 2024 at 9:00 a.m. Eastern Time. The Special Meeting will be held exclusively via the Internet in a virtual meeting format at www.proxydocs.com/CUE . There will not be a physical meeting location, and stockholders will not be able to attend the Special Meeting in person. Except where the context otherwise requires, references to “Cue Biopharma,” “the Company,” “we,” “us,” “our” and similar terms refer to Cue Biopharma, Inc. and its consolidated subsidiary. References to our website are inactive textual references only and the contents of our website are not incorporated by reference into this Proxy Statement. This Proxy Statement and the enclosed proxy card are being furnished in connection with the solicitation of proxies by our board of directors for use at the Special Meeting and at any adjournment or postponement of that meeting. All proxies will be